Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
+3S
company
About
+3S specializes in the research, development, production and operation of antitoxin and antiserum biological products.
- 101 - 250
Highlights
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- ¥50M
- Industries
- Biotechnology,Manufacturing,Medical,Pharmaceutical
- Founded date
- Nov 9, 1999
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Serum Biotech is a high-tech enterprise specialized in research, development, production, and sales of antitoxin and antiserum products in China.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥50M
+3S has raised a total of
¥50M
in funding over 2 rounds. Their latest funding was raised on
Dec 27, 2016 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 27, 2016 | Post-IPO Equity | ¥50M | 3 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
+3S is funded by 3 investors.
Tibet Jiuzheng Capital Investment
and Optical Valley Venture Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Post-IPO Equity |
Optical Valley Venture Capital
|
— | Post-IPO Equity |
Ch-gemstone capital
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
